Liposomal Daunorubicin and Cytarabine, a Potential Therapy for Blastic Plasmacytoid Dendritic Cell Neoplasm
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare aggressive malignancy with poor outcomes. Although novel options like tagraxofusp, a CD123-directed cytotoxin, has emerged and is promising, treatment options are very limited in the relapsed and recurrent setting. We present a case of r...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2022-11-01
|
| Series: | Journal of Investigative Medicine High Impact Case Reports |
| Online Access: | https://doi.org/10.1177/23247096221127114 |
| _version_ | 1811243564218187776 |
|---|---|
| author | Prashanth Ashok Kumar MBBS Mulham Ombada MBBS Gayatri Pemmasani MBBS Ajay Tambe MBBS Katalin Banki MD Teresa Gentile MD, PhD |
| author_facet | Prashanth Ashok Kumar MBBS Mulham Ombada MBBS Gayatri Pemmasani MBBS Ajay Tambe MBBS Katalin Banki MD Teresa Gentile MD, PhD |
| author_sort | Prashanth Ashok Kumar MBBS |
| collection | DOAJ |
| description | Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare aggressive malignancy with poor outcomes. Although novel options like tagraxofusp, a CD123-directed cytotoxin, has emerged and is promising, treatment options are very limited in the relapsed and recurrent setting. We present a case of refractory BPDCN in a 62-year-old man who showed a complete bone marrow response to liposomal daunorubicin and cytarabine (vyxeos). |
| first_indexed | 2024-04-12T14:09:33Z |
| format | Article |
| id | doaj.art-2b667d66cca547d99639e1ebad13b826 |
| institution | Directory Open Access Journal |
| issn | 2324-7096 |
| language | English |
| last_indexed | 2024-04-12T14:09:33Z |
| publishDate | 2022-11-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Journal of Investigative Medicine High Impact Case Reports |
| spelling | doaj.art-2b667d66cca547d99639e1ebad13b8262022-12-22T03:29:56ZengSAGE PublishingJournal of Investigative Medicine High Impact Case Reports2324-70962022-11-011010.1177/23247096221127114Liposomal Daunorubicin and Cytarabine, a Potential Therapy for Blastic Plasmacytoid Dendritic Cell NeoplasmPrashanth Ashok Kumar MBBS0Mulham Ombada MBBS1Gayatri Pemmasani MBBS2Ajay Tambe MBBS3Katalin Banki MD4Teresa Gentile MD, PhD5SUNY Upstate University Hospital, Syracuse, USASUNY Upstate University Hospital, Syracuse, USASUNY Upstate University Hospital, Syracuse, USASUNY Upstate University Hospital, Syracuse, USASUNY Upstate University Hospital, Syracuse, USASUNY Upstate University Hospital, Syracuse, USABlastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare aggressive malignancy with poor outcomes. Although novel options like tagraxofusp, a CD123-directed cytotoxin, has emerged and is promising, treatment options are very limited in the relapsed and recurrent setting. We present a case of refractory BPDCN in a 62-year-old man who showed a complete bone marrow response to liposomal daunorubicin and cytarabine (vyxeos).https://doi.org/10.1177/23247096221127114 |
| spellingShingle | Prashanth Ashok Kumar MBBS Mulham Ombada MBBS Gayatri Pemmasani MBBS Ajay Tambe MBBS Katalin Banki MD Teresa Gentile MD, PhD Liposomal Daunorubicin and Cytarabine, a Potential Therapy for Blastic Plasmacytoid Dendritic Cell Neoplasm Journal of Investigative Medicine High Impact Case Reports |
| title | Liposomal Daunorubicin and Cytarabine, a Potential Therapy for Blastic Plasmacytoid Dendritic Cell Neoplasm |
| title_full | Liposomal Daunorubicin and Cytarabine, a Potential Therapy for Blastic Plasmacytoid Dendritic Cell Neoplasm |
| title_fullStr | Liposomal Daunorubicin and Cytarabine, a Potential Therapy for Blastic Plasmacytoid Dendritic Cell Neoplasm |
| title_full_unstemmed | Liposomal Daunorubicin and Cytarabine, a Potential Therapy for Blastic Plasmacytoid Dendritic Cell Neoplasm |
| title_short | Liposomal Daunorubicin and Cytarabine, a Potential Therapy for Blastic Plasmacytoid Dendritic Cell Neoplasm |
| title_sort | liposomal daunorubicin and cytarabine a potential therapy for blastic plasmacytoid dendritic cell neoplasm |
| url | https://doi.org/10.1177/23247096221127114 |
| work_keys_str_mv | AT prashanthashokkumarmbbs liposomaldaunorubicinandcytarabineapotentialtherapyforblasticplasmacytoiddendriticcellneoplasm AT mulhamombadambbs liposomaldaunorubicinandcytarabineapotentialtherapyforblasticplasmacytoiddendriticcellneoplasm AT gayatripemmasanimbbs liposomaldaunorubicinandcytarabineapotentialtherapyforblasticplasmacytoiddendriticcellneoplasm AT ajaytambembbs liposomaldaunorubicinandcytarabineapotentialtherapyforblasticplasmacytoiddendriticcellneoplasm AT katalinbankimd liposomaldaunorubicinandcytarabineapotentialtherapyforblasticplasmacytoiddendriticcellneoplasm AT teresagentilemdphd liposomaldaunorubicinandcytarabineapotentialtherapyforblasticplasmacytoiddendriticcellneoplasm |